Models and discovery strategies for new therapies of retinoblastoma

Samuel K. Houston, Theodore Lampidis, Timothy G. Murray

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Retinoblastoma is the most common primary intraocular malignancy in children. Treatment success approaches 100% at specialized centers with globe-salvaging modalities. Primary management of retinoblastoma consists of chemoreduction with local consolidation, although newer techniques include local delivery via intra-arterial chemotherapy, periocular, or intravitreal injection. Animal models have played an integral role in the understanding of retinoblastoma tumorigenesis and have contributed to the development of globe-salvaging treatments. Areas covered: This review focuses on the use of models and discovery strategies on translational research in retinoblastoma. The article reviews gene expression profiling, knockout models, and transgenic animal models. In addition, the review discusses translational applications of hyperthermia, chemotherapy (systemic and local delivery), radiation therapy, and novel targets such as hypoxia, angiogenesis, cellular metabolism, and tumor suppressor functions. Expert opinion: Retinoblastoma treatment success has been driven by translational research using novel animal models and discovery strategies. Future developments require further understanding of the unique genetic events that result in tumor growth and development, as well as an understanding of the complex interactions of tumor cells with the local tumor microenvironment and how this affects tumor growth, metastasis, and response to treatment.

Original languageEnglish
Pages (from-to)383-394
Number of pages12
JournalExpert Opinion on Drug Discovery
Volume8
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Retinoblastoma
Translational Medical Research
Animal Models
Neoplasms
Intraocular Injections
Therapeutics
Drug Therapy
Cell Hypoxia
Genetically Modified Animals
Intravitreal Injections
Tumor Microenvironment
Expert Testimony
Gene Expression Profiling
Growth and Development
Cell Communication
Carcinogenesis
Fever
Radiotherapy
Neoplasm Metastasis
Growth

Keywords

  • Angiogenesis
  • Hypoxia
  • Metabolism
  • Retinoblastoma

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Models and discovery strategies for new therapies of retinoblastoma. / Houston, Samuel K.; Lampidis, Theodore; Murray, Timothy G.

In: Expert Opinion on Drug Discovery, Vol. 8, No. 4, 01.04.2013, p. 383-394.

Research output: Contribution to journalArticle

Houston, Samuel K. ; Lampidis, Theodore ; Murray, Timothy G. / Models and discovery strategies for new therapies of retinoblastoma. In: Expert Opinion on Drug Discovery. 2013 ; Vol. 8, No. 4. pp. 383-394.
@article{669e42b87e6f4932b4965c62dae39b82,
title = "Models and discovery strategies for new therapies of retinoblastoma",
abstract = "Introduction: Retinoblastoma is the most common primary intraocular malignancy in children. Treatment success approaches 100{\%} at specialized centers with globe-salvaging modalities. Primary management of retinoblastoma consists of chemoreduction with local consolidation, although newer techniques include local delivery via intra-arterial chemotherapy, periocular, or intravitreal injection. Animal models have played an integral role in the understanding of retinoblastoma tumorigenesis and have contributed to the development of globe-salvaging treatments. Areas covered: This review focuses on the use of models and discovery strategies on translational research in retinoblastoma. The article reviews gene expression profiling, knockout models, and transgenic animal models. In addition, the review discusses translational applications of hyperthermia, chemotherapy (systemic and local delivery), radiation therapy, and novel targets such as hypoxia, angiogenesis, cellular metabolism, and tumor suppressor functions. Expert opinion: Retinoblastoma treatment success has been driven by translational research using novel animal models and discovery strategies. Future developments require further understanding of the unique genetic events that result in tumor growth and development, as well as an understanding of the complex interactions of tumor cells with the local tumor microenvironment and how this affects tumor growth, metastasis, and response to treatment.",
keywords = "Angiogenesis, Hypoxia, Metabolism, Retinoblastoma",
author = "Houston, {Samuel K.} and Theodore Lampidis and Murray, {Timothy G.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1517/17460441.2013.772975",
language = "English",
volume = "8",
pages = "383--394",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Models and discovery strategies for new therapies of retinoblastoma

AU - Houston, Samuel K.

AU - Lampidis, Theodore

AU - Murray, Timothy G.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Introduction: Retinoblastoma is the most common primary intraocular malignancy in children. Treatment success approaches 100% at specialized centers with globe-salvaging modalities. Primary management of retinoblastoma consists of chemoreduction with local consolidation, although newer techniques include local delivery via intra-arterial chemotherapy, periocular, or intravitreal injection. Animal models have played an integral role in the understanding of retinoblastoma tumorigenesis and have contributed to the development of globe-salvaging treatments. Areas covered: This review focuses on the use of models and discovery strategies on translational research in retinoblastoma. The article reviews gene expression profiling, knockout models, and transgenic animal models. In addition, the review discusses translational applications of hyperthermia, chemotherapy (systemic and local delivery), radiation therapy, and novel targets such as hypoxia, angiogenesis, cellular metabolism, and tumor suppressor functions. Expert opinion: Retinoblastoma treatment success has been driven by translational research using novel animal models and discovery strategies. Future developments require further understanding of the unique genetic events that result in tumor growth and development, as well as an understanding of the complex interactions of tumor cells with the local tumor microenvironment and how this affects tumor growth, metastasis, and response to treatment.

AB - Introduction: Retinoblastoma is the most common primary intraocular malignancy in children. Treatment success approaches 100% at specialized centers with globe-salvaging modalities. Primary management of retinoblastoma consists of chemoreduction with local consolidation, although newer techniques include local delivery via intra-arterial chemotherapy, periocular, or intravitreal injection. Animal models have played an integral role in the understanding of retinoblastoma tumorigenesis and have contributed to the development of globe-salvaging treatments. Areas covered: This review focuses on the use of models and discovery strategies on translational research in retinoblastoma. The article reviews gene expression profiling, knockout models, and transgenic animal models. In addition, the review discusses translational applications of hyperthermia, chemotherapy (systemic and local delivery), radiation therapy, and novel targets such as hypoxia, angiogenesis, cellular metabolism, and tumor suppressor functions. Expert opinion: Retinoblastoma treatment success has been driven by translational research using novel animal models and discovery strategies. Future developments require further understanding of the unique genetic events that result in tumor growth and development, as well as an understanding of the complex interactions of tumor cells with the local tumor microenvironment and how this affects tumor growth, metastasis, and response to treatment.

KW - Angiogenesis

KW - Hypoxia

KW - Metabolism

KW - Retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=84875393115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875393115&partnerID=8YFLogxK

U2 - 10.1517/17460441.2013.772975

DO - 10.1517/17460441.2013.772975

M3 - Article

C2 - 23427911

AN - SCOPUS:84875393115

VL - 8

SP - 383

EP - 394

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 4

ER -